Treatment of Cachexia: An Overview of Recent Developments

Stephan von Haehling, Stefan D. Anker

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of them in patients with cancer. The aim of this article was to summarize clinical trials published over the past 2years. Therapeutic approaches discussed include appetite stimulants, such as megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs, such as thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin; nutritional support, and anabolics, such as enobosarm and testosterone.

Original languageEnglish
Pages (from-to)866-872
Number of pages7
JournalJournal of the American Medical Directors Association
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Cachexia
Ghrelin
Appetite Stimulants
Clinical Trials
Megestrol Acetate
Thalidomide
Survival
Nutritional Support
Carnitine
Muscle Strength
Melatonin
Interleukin-1
Testosterone
Skeletal Muscle
Chronic Disease
Anti-Inflammatory Agents
Monoclonal Antibodies
Quality of Life
Exercise
Therapeutics

Keywords

  • Cachexia
  • Cancer
  • Therapy
  • Wasting

ASJC Scopus subject areas

  • Medicine(all)
  • Nursing(all)
  • Health Policy

Cite this

Treatment of Cachexia : An Overview of Recent Developments. / von Haehling, Stephan; Anker, Stefan D.

In: Journal of the American Medical Directors Association, Vol. 15, No. 12, 01.12.2014, p. 866-872.

Research output: Contribution to journalArticle

von Haehling, Stephan ; Anker, Stefan D. / Treatment of Cachexia : An Overview of Recent Developments. In: Journal of the American Medical Directors Association. 2014 ; Vol. 15, No. 12. pp. 866-872.
@article{a8afc1bf26414bd79c936f71feb94c44,
title = "Treatment of Cachexia: An Overview of Recent Developments",
abstract = "Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of them in patients with cancer. The aim of this article was to summarize clinical trials published over the past 2years. Therapeutic approaches discussed include appetite stimulants, such as megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs, such as thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin; nutritional support, and anabolics, such as enobosarm and testosterone.",
keywords = "Cachexia, Cancer, Therapy, Wasting",
author = "{von Haehling}, Stephan and Anker, {Stefan D.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.jamda.2014.09.007",
language = "English",
volume = "15",
pages = "866--872",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Treatment of Cachexia

T2 - An Overview of Recent Developments

AU - von Haehling, Stephan

AU - Anker, Stefan D.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of them in patients with cancer. The aim of this article was to summarize clinical trials published over the past 2years. Therapeutic approaches discussed include appetite stimulants, such as megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs, such as thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin; nutritional support, and anabolics, such as enobosarm and testosterone.

AB - Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of them in patients with cancer. The aim of this article was to summarize clinical trials published over the past 2years. Therapeutic approaches discussed include appetite stimulants, such as megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs, such as thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin; nutritional support, and anabolics, such as enobosarm and testosterone.

KW - Cachexia

KW - Cancer

KW - Therapy

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=84912098360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912098360&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2014.09.007

DO - 10.1016/j.jamda.2014.09.007

M3 - Article

C2 - 25455531

AN - SCOPUS:84912098360

VL - 15

SP - 866

EP - 872

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 12

ER -